Search

What an EHA Innovation Grant supports

Our EHA Innovation Grant supports high-quality clinical or translational research in hematology. To reflect the collaborative spirit of the grant, no more than 40% of the total grant should be allocated to one member of the consortium.

Read more

Abstract Submission & Travel Grant Application

Late Poster Submission is now closed.

Read more

Abstract & travel grant submission

Abstract submission is closed

Abstract procedurePlease note that the submission of an abstract constitutes a formal commitment by the presenting author to present the abstract (if accepted) orally or as a poster in the session at the time assigned by the…

Read more

EHA Diversity, Equity, and Inclusion Award 2024

The EHA Diversity, Equity, and Inclusion (DEI) Award celebrates achievements that foster inclusivity. It recognizes efforts taken by individuals, teams, or organizations (collectively “candidate”) to promote DEI within leadership, initiatives, and overall work.

Read more

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more

Call for interest

As a member of an EHA committee or taskforce, you’ll be instrumental in taking our ambitions to the next level.

Read more